Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner: population-based and in vitro studies

2012389 citationsJournal Article

Authors

Hsiao-Ping Chen · National Chung Hsing University

Jeng‐Jer Shieh · National Chung Hsing University

Chia‐Che Chang · China Medical University

Tzu-Ting Chen · Taichung Veterans General Hospital

Jaw‐Town Lin · I-Shou University

Ming‐Shiang Wu · National Taiwan University Hospital

Jeng-Horng Lin

Abstract

Use of metformin is associated with a decreased risk of HCC in diabetic patients in a dose-dependent manner, via inhibition of hepatoma cells proliferation and induction of cell cycle arrest at G0/G1 phase.

Topics & Keywords

Metabolism, Diabetes, and Cancer PI3K/AKT/mTOR signaling in cancer Cancer-related Molecular Pathways

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Gut

Volume 62, Issue 4, pp. 606-615

DOI: 10.1136/gutjnl-2011-301708

Field-Weighted Citation Impact: 13.66